Navigation Links
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
Date:6/9/2008

tion (ADA) in San Francisco.

BYETTA is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione, but have not achieved adequate glycemic control.

"Diabetes is a lifelong condition that requires constant management of blood glucose or blood sugar as well as weight. In DURATION-1 trial, patients significantly reduced their blood glucose levels and, on average, lost a total of over nine pounds. These improvements were sustained for a year," said John B. Buse, M.D., Ph.D., Professor of Medicine, Director of the Diabetes Care Center, and Chief of the Division of Endocrinology at the University of North Carolina School of Medicine in Chapel Hill. "Importantly, the study results also showed that steady-state levels of exenatide may result in improvements in a variety of glucose parameters. If approved, exenatide once weekly may provide patients with a treatment option that is on board 24 hours a day, seven days a week, helping to manage their blood sugar and, secondarily, their weight."

Study Design and Findings

The Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide ONce Weekly (DURATION-1) study was a 30-week, randomized, open-label study of 295 patients with type 2 diabetes (baseline values: A1C 8.3%+/-1.0, FPG 169+/-43 mg/dL, weight 225+/-44lbs., BMI 35+/-5.0 kg/m2, diabetes duration 6.7+/-5.0 years; mean+/-SD) who were treated with exenatide once weekly 2.0 mg or BYETTA twice daily as outlined in the approved label subcutaneously. Following the first 30 weeks of treatment, 258 patients entered an open-label treatment with exenatide once weekly. Patients either remained on exenatide once weekly or switched from BYETTA to exenatide once weekly for an additional 22 weeks.
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. Is PCI Safe, Effective After Clot-Busters for Heart Attack?
6. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Helping Families Cope After an Injury
9. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015  Pomerantz LLP ... Pharmaceuticals, Inc. ("Vitae" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Vitae and certain of its officers and/or directors have ... Act of 1934.  On February 27, ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers at ... of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) ... share. Concerned SLXP investors are encouraged to contact attorney ... The investigation focuses upon the shareholder value of ... shareholders would receive only $158.00 per share in cash. ...
(Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... Aliso Viejo, California (PRWEB) March 01, 2015 ... have announced a new transition pack for ... users to add accordion style transitions to any FCPX ... Studios. “We’ve given our users the tools needed to ... FCPX media.” , The user gets many different controls ...
(Date:2/28/2015)... 01, 2015 Heart diseases are on ... percent of urban adult population and 5 percent of ... diseases and 20-30 percent of them require specialized investigation ... and coronary vascular diseases (CVD). , A division of ... market research report titled “Indian Coronary Stent Market Forecast ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... 2015 Vancouver personal injury lawyers at Jiwa ... affected by time limits. They stated that in many cases, ... or even nullify it. Many a time, delays in making ... rights under BC law. As a result, experts at Jiwa ... should consult a personal injury lawyer in order to know ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2
... Steven Reinberg HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... -- defined as men who down five or more drinks at ... one time, federal researchers reported Tuesday. Of the 17 percent ... 24 years old. But those 65 and older engage in the ...
... , INDIANAPOLIS -- The School of Science at Indiana ... Modeling and Computational Science, an interdisciplinary endeavor dedicated to ... the environment, and computer science. iM2CS,s parallel mission is ... the scientific issues with which they will be faced. ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Dutch researchers ... the drug Nexavar (sorafenib) in fighting a tough-to-treat form ... experimental drug known as ganetespib showed promise in laboratory ... studies were to be presented Tuesday at an American ...
... Island Hospital has found that collaborative ,behavioral management may ... users who are paroled. The findings have important implications ... U.S. community correctional population. The study is published in ... of print. In the U.S., over 700,000 inmates ...
... January issue of Health Affairs assesses real-world ... chronic disease that affects nearly 26 million Americans. ... systematically reviewed the published literature and analyzed 28 studies ... trial in real-world settings. Published in 2002, this major ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- The ... the risk of heart attack, a new review finds. ... trials involving Pradaxa that included more than 30,000 patients. This ... to tease out a pattern that might not show up ...
Cached Medicine News:Health News:One in Six Americans Binge Drink: CDC 2Health News:One in Six Americans Binge Drink: CDC 3Health News:Revealing causality 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 2Health News:Behavioral management to reduce substance abuse, crime and re-arrest for drug-involved parolees 3Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:New Blood Thinner Linked to Higher Heart Attack Risk 2Health News:New Blood Thinner Linked to Higher Heart Attack Risk 3
... first instrument engineered to match the speed ... cycling system is based on heat transfer ... microcapillary tubes or thin walled micorcentrifuge tubes. ... of high velocity air results in nearly ...
... Excellent performance, small footprint, simple intuitive ... the Primus 25 the ideal personal cycler ... ,The flexiblock design and the self-adjusting heated ... or 13x 0.5ml vessels or a microplate ...
... day-to-day temperature cycling ,Unmatched ... ,30% reduction in cycling ... coolant-based cyclers ,4 programmable ... ,Options for oil-free and ...
... rapid, real-time thermal cycler used for identifying ... much of the testing process, and making ... the fastest, easiest to use, and most ... SmartCycler delivers highly accurate and consistent test ...
Medicine Products: